An interventional study of ReDura Onlay and DuraGen in Neurosurgical Repairs, sponsored by Medprin Regenerative Medical Technologies Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-07-08.
Sponsored by Medprin Regenerative Medical Technologies Co., Ltd. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
4.1 Subjects who meet the inclusion criteria are randomized in accordance with the admission time; routine blood test, liver and kidney function test, as well as cellular and humoral immunity test are conducted prior to the surgery.
4.2 Location, characteristics and size of the defects,as well as the conditions of surgical incision are all observed intra-operatively.
4.3 Dura mater membrane repairing surgeries are conducted by closely attaching either an appropriately-sized test product or reference product to the defected part of dura mater membrane, before the incision in the skull is closed by using a conventional approach.
4.4 The subjects'conditions are reviewed on Day 1, 3, 5, 7 and 10 post operations, respectively.
4.5 Lumbar puncture is conducted on Day 10±2 post operation based on the subject's conditions, in order to measure the intracranial pressure and test for cerebrospinal fluid leakage; routine blood, liver and kidney function, as well as cellular and humoral immunity are re-tested on Day 10±2 post operation and the values obtained are compared with the pre-operative baseline measurements and recorded, so as to evaluate the clinical significance; On Day 10±2 post operation, cerebrospinal fluid leakage or subcutaneous effusion are examined by CT scan and clinical examinations, so as to assess the relationship of such events to the test/reference product.
4.6 For subjects who received a re-operation in the same location or a second neurosurgery, the conditions of test product or reference product in the repairing site is observed, e.g. examine (combined with histological test) product adhesion with cerebral tissues and etc.
4.7 The subjects are asked to attend a return visit or a telephone follow-up session on Day 90±10 and 180±20 post operation.
Medprin Regenerative Medical Technologies Co., Ltd. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The Dural Repair Patch manufactured by Guangzhou Medprin Regenerative Medical Technologies Co., Ltd.
Device: ReDura Onlay
Dural Graft Matrix manufactured by Integra LifeSciences (U.S.) Corporation.
Device: DuraGen
Subject will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of ReDura Onlay.
Subject will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of DuraGen.
Rate of successful prevention of CSF leakage
on Day 10±2 post operation, occurrence of CSF leakage is checked on both CT and clinical examination
Time frame: Day 10±2 post operation
Healing of scalp incision
the healing of scalp incision is reviewed on Day 3, Day 5, Day7, Day 10, Month 3 and Month 6, respectively.
Time frame: 6 month
The record gives a start of Apr 2014, a primary completion of Dec 2014 and a completion of May 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medprin Regenerative Medical Technologies Co., Ltd. →